Ann Lab Med.  2015 Mar;35(2):254-256. 10.3343/alm.2015.35.2.254.

Pediatric B-cell Lymphoma, Unclassifiable, With Intermediate Features Between Those of Diffuse Large B-cell Lymphoma and Burkitt Lymphoma: A Report of Two Cases

• Zhang S
• Wilson D
• Czader M

• KMID: 2363189
• DOI: http://doi.org/10.3343/alm.2015.35.2.254

Abstract

No abstract available.

MeSH Terms

Adolescent
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Burkitt Lymphoma/*pathology
Child, Preschool
Cyclophosphamide/therapeutic use
Doxorubicin/therapeutic use
Female
Gene Rearrangement
Herpesvirus 4, Human/metabolism
Humans
Immunohistochemistry
Lymphoma, B-Cell/*diagnosis/drug therapy
Lymphoma, Large B-Cell, Diffuse/*pathology
Male
Prednisone/therapeutic use
Proto-Oncogene Proteins c-myc/genetics
Tomography, X-Ray Computed
Vincristine/therapeutic use
Viral Matrix Proteins/immunology/metabolism
Cyclophosphamide
Doxorubicin
Prednisone
Proto-Oncogene Proteins c-myc
Vincristine
Viral Matrix Proteins

Figure

• 

  Fig. 1 Morphologic (A, Hematoxylin and eosin staining, ×50) and immunophenotypic (B-F, ×20) features of B-cell lymphoma, unclassifiable, with intermediate features between DLBCL and Burkitt lymphoma. (B) CD20, (C) BCL-6, (D) BCL-2, (E) MUM-1, and (F) Ki-67.

Reference

1. Carbone A, Gloghini A, Aiello A, Testi A, Cabras A. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Hum Pathol. 2010; 41:621–631. PMID: 20398809.

2. Kluin PM, Harris NL, Stein H, Leoncini L, Raphael M, Campo E, et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In : Swerdlow SH, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press;2008. p. 265–266.

3. Liang X, Greffe B, Cook B, Giller R, Graham DK, McGranahan AN, et al. Gray zone lymphomas in pediatric patients. Pediatr Dev Pathol. 2011; 14:57–63. PMID: 20331368.

4. Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, Garcia M, et al. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer. 2012; 118:1566–1573. PMID: 21882178.

5. Salaverria I, Siebert R. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol. 2011; 29:1835–1843. PMID: 21482997.

6. Ahn JY, Seo YH, Park PW, Kim KH, Park MJ, Jeong JH, et al. A case of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a Korean child. Ann Lab Med. 2012; 32:162–166. PMID: 22389885.

7. Lu B, Zhou C, Yang W, Huang H, Gao Z, He Y, et al. Morphological, immunophenotypic and molecular characterization of mature aggressive B-cell lymphomas in Chinese pediatric patients. Leuk Lymphoma. 2011; 52:2356–2364. PMID: 21740296.

8. Reiter A, Schrappe M, Parwaresch R, Henze G, Müller-Weihrich S, Sauter S, et al. Non-Hodgkin's lymphomas of childhood and adolescence: results of a treatment stratified for biologic subtypes and stage--a report of the Berlin-Frankfurt-Münster Group. J Clin Oncol. 1995; 13:359–372. PMID: 7844597.

9. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, Michon J, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007; 109:2736–2743. PMID: 17138821.

10. Patte C, Auperin A, Gerrad M, Michon J, Pinkerton R, Sposto R, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007; 109:2773–2780. PMID: 17132719.